Findings on femoral fractures in older adults with type 2 diabetes concern a specific population and comparator. In those matched records, one-year rates were 0.3% for semaglutide versus 0.5% for a DPP-4 inhibitor, and 0.2% for tirzepatide versus 0.4% for a DPP-4 inhibitor in a separate cohort. The participants were at least 65 and had overweight or obesity. The study found an association and could not establish causation [1].
What does the Wegovy label say?
In the cardiovascular outcomes trial, hip or pelvic fractures were reported in 1.0% of women receiving Wegovy versus 0.2% with placebo (24 of 2,448 versus 5 of 2,424). Among adults aged 75 and older, they were reported in 2.4% versus 0.6% (17 of 703 versus 4 of 663) [2]. These groups can overlap. In a separate trial in adults with MASH, fractures were reported in 4.4% with Wegovy versus 3.3% with placebo [2]. That figure covers fractures generally, while the cardiovascular trial figures above describe hip and pelvic fractures.
What did the broader fracture evidence find?
A 2025 review of randomized trials in people with type 2 diabetes estimated a fracture risk ratio of 0.80 (95% CI 0.47 to 1.36). The interval leaves considerable uncertainty in both directions [3]. A later review that also included observational studies found no clear difference in overall fractures, with substantial variation between studies [4].
What happens to bone density?
A 52-week randomized study enrolled 64 adults at increased fracture risk. Once-weekly semaglutide showed no clear difference versus placebo on the primary bone formation marker. Bone density was lower at the lumbar spine and total hip, and a marker of bone breakdown was higher. The study was too small to determine whether fractures became more common[5].
If you have osteoporosis, a prior fracture or a high risk of falls, discuss your bone health with the clinician who manages your treatment.